CONGENITAL ADRENAL HYPERPLASIA
Clinical trials for CONGENITAL ADRENAL HYPERPLASIA explained in plain language.
Never miss a new study
Get alerted when new CONGENITAL ADRENAL HYPERPLASIA trials appear
Sign up with your email to follow new studies for CONGENITAL ADRENAL HYPERPLASIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare hormone disorder: atumelnant trial launches
Disease control Recruiting nowThis study tests an experimental drug called atumelnant in 150 adults with classic congenital adrenal hyperplasia (CAH), a genetic condition that disrupts hormone production. Participants will receive either atumelnant or a placebo to see if the drug can better control hormone le…
Matched conditions: CONGENITAL ADRENAL HYPERPLASIA
Phase: PHASE3 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Disease control
Last updated May 17, 2026 00:52 UTC
-
New hope for rare hormone disorder: lu AG13909 enters human trials
Disease control Recruiting nowThis study tests a new medicine called Lu AG13909 in 42 adults with congenital adrenal hyperplasia (CAH), a rare genetic condition that disrupts hormone production. The goal is to check the drug's safety, how the body processes it, and its effects on hormone levels. Participants …
Matched conditions: CONGENITAL ADRENAL HYPERPLASIA
Phase: PHASE1, PHASE2 • Sponsor: H. Lundbeck A/S • Aim: Disease control
Last updated May 17, 2026 00:44 UTC
-
New hope for kids with rare hormone disorder: drug may cut steroid doses
Disease control Recruiting nowThis study tests a new medicine called atumelnant in children aged 1 to 18 with classic congenital adrenal hyperplasia, a genetic condition that disrupts hormone balance. The goal is to see if the drug can safely control hormone levels and reduce the need for daily steroid medica…
Matched conditions: CONGENITAL ADRENAL HYPERPLASIA
Phase: PHASE2, PHASE3 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New Once-Daily pill could simplify CAH treatment
Disease control Recruiting nowThis study tests if a once-daily dual-release hydrocortisone works better than standard multiple-dose therapy for people with congenital adrenal hyperplasia (CAH). Researchers will measure cholesterol, blood sugar, blood pressure, bone health, and quality of life in 150 adults. T…
Matched conditions: CONGENITAL ADRENAL HYPERPLASIA
Phase: PHASE4 • Sponsor: Federico II University • Aim: Disease control
Last updated May 12, 2026 13:39 UTC
-
New hope for CAH: Long-Term drug trial launches
Disease control Recruiting nowThis study looks at the long-term safety and effectiveness of a drug called atumelnant (CRN04894) for people with classic congenital adrenal hyperplasia (CAH). About 150 adults who have already completed a previous study with this drug will continue treatment. Researchers will mo…
Matched conditions: CONGENITAL ADRENAL HYPERPLASIA
Phase: PHASE2 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Disease control
Last updated May 04, 2026 16:31 UTC
-
Promising CAH drug now being studied in infants and toddlers
Disease control Recruiting nowThis study tests a drug called crinecerfont in 6 children under 2 years old who have congenital adrenal hyperplasia (CAH). The goal is to see how the drug moves through the body and if it is safe. All children will receive the drug, and researchers will monitor side effects and d…
Matched conditions: CONGENITAL ADRENAL HYPERPLASIA
Phase: PHASE2 • Sponsor: Neurocrine Biosciences • Aim: Disease control
Last updated May 01, 2026 16:00 UTC
-
New registry aims to shed light on rare diseases
Knowledge-focused Recruiting nowThis study is creating a large database to collect information about people with rare diseases like amyloidosis, sarcoidosis, and many others. Researchers will track participants' health, treatments, and outcomes over time to better understand these conditions. The goal is to imp…
Matched conditions: CONGENITAL ADRENAL HYPERPLASIA
Sponsor: Hospital Italiano de Buenos Aires • Aim: Knowledge-focused
Last updated May 11, 2026 20:49 UTC